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Abstract
Purpose :
Risuteganib is a small synthetic peptide that regulates select
integrin functions involved in the pathogenesis of dry age-related
macular degeneration (AMD). This study evaluated the safety and
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efcay of risuteganib for the treatment of dry AMD.
Methods :
Randomized, double-masked, placebo-controlled Phase 2
study in eyes with intermediate dry AMD presenting with best-
corrected visual acuity (BCVA) between 20/40-20/200 was conducted
across multiple centers in the United States. Patients were
randomized to receive either intravitreal 1.0mg risuteganib or sham
injection at baseline. At week 16, patients in the risuteganib group
received a second dose and the sham group crossed over and receive
a single dose of 1.0mg risuteganib. The primary endpoint was the
percentage of population with ≥ 8 letters BCVA gain from baseline to
week 28 in 1.0mg risuteganib vs baseline to week 12 for sham.
Results :
Forty-fve patients were enrolled in the study. At baseline,
mean patient age was 78.8 and 75.9 years and mean baseline BCVA
was 67.1 and 64.4 letters in the sham and risuteganib groups,
respectively. The primary endpoint was met; 48% of patients in the
risuteganib group at week 28 and 7% of patients in the sham group at
week 12 gained > 8 letters from baseline (p=0.013). Of the risuteganib
treated patients, 20% gained > 15 letters at week 28; no patients in the
sham group at week 12 had this gain. On a post-hoc masked analysis
by 2 independent reading centers, greater outer retinal and
photoreceptor thickness and volume and smaller ellipsoid zone defect
area in the central 1 mm zone at baseline were associated with
increased BCVA response to risuteganib. Risuteganib demonstrated a
good safety profle in this study.
Conclusions :
Risuteganib showed signifcant beneft over sham in
patients with dry AMD with respect to proportion of patients gaining >
8 letters of BCVA from baseline. Furthermore, post hoc analysis
provides preliminary insights into baseline anatomic features that may
help to determine likelihood of BCVA response to risuteganib. These
fndings will be confrmed in an upcoming larger trial.
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